Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomised phase II trial of olaparib, weekly paclitaxel or olaparib + cediranib in platinum-resistant ovarian cancer
2016-000559-28Phase 2Unknown
- Sponsor
- University of Oxford
- Start
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in ovarian cancer comparing Olaparib monotherapy, Weekly paclitaxel chemotherapy and Olaparib + cediranib combination (3 arms). Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
olaparibcediranibpaclitaxel
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on 2016-000559-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000559-28.